Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEZS Aeterna Zentaris	$3.29 +21.8%	$3.57	$3.96 ▼ $12.00	$5.90M	1.55	7,305 shs	93,792 shs
MNK Mallinckrodt		$0.34	$0.75 ▼ $6.42	$1.58M	N/A	2.62 million shs	39,227 shs
NRBO NeuroBo Pharmaceuticals	$0.65 +1.7%	$0.66	$2.08 ▼ $4.41	$5.60M	-0.26	39,605 shs	84,345 shs
SPRB Spruce Biosciences	$8.20 -3.5%	$7.11	$0.06 ▼ $0.61	$4.61M	2.43	802,052 shs	5,615 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEZS Aeterna Zentaris	0.00%	+15.38%	-16.96%	-7.37%	-46.79%
MNK Mallinckrodt	0.00%	0.00%	0.00%	0.00%	0.00%
NRBO NeuroBo Pharmaceuticals	0.00%	+1.56%	-11.77%	-17.70%	-80.88%
SPRB Spruce Biosciences	0.00%	-8.99%	-6.87%	+73.54%	-77.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AEZS Aeterna Zentaris	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MNK Mallinckrodt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NRBO NeuroBo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SPRB Spruce Biosciences	2.3315 of 5 stars	3.0	3.0	0.0	0.0	2.5	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AEZS Aeterna Zentaris	0.00	N/A	N/A	N/A
MNK Mallinckrodt	0.00	N/A	N/A	N/A
NRBO NeuroBo Pharmaceuticals	0.00	N/A	N/A	N/A
SPRB Spruce Biosciences	2.00	Hold	$131.25	1,500.61% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AEZS Aeterna Zentaris	$2.37M	2.48	N/A	N/A	$14.99 per share	0.22
MNK Mallinckrodt	N/A	N/A	N/A	N/A	$47.48 per share	N/A
NRBO NeuroBo Pharmaceuticals	N/A	N/A	N/A	N/A	$1.50 per share	N/A
SPRB Spruce Biosciences	$4.91M	0.94	N/A	N/A	$1.88 per share	4.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AEZS Aeterna Zentaris	-$16.55M	-$14.86	N/A	∞	N/A	-760.32%	-83.45%	-45.76%	N/A
MNK Mallinckrodt	N/A	-$116.19	N/A	N/A	N/A	-82.59%	20.32%	2.49%	N/A
NRBO NeuroBo Pharmaceuticals	-$12.47M	N/A	0.00	N/A	N/A	N/A	-189.12%	-122.31%	11/5/2025 (Estimated)
SPRB Spruce Biosciences	-$47.92M	-$99.25	N/A	N/A	N/A	-555.23%	-62.10%	-47.49%	11/10/2025 (Estimated)

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AEZS Aeterna Zentaris	N/A	N/A	N/A	N/A	N/A
MNK Mallinckrodt	N/A	N/A	N/A	N/A	N/A
NRBO NeuroBo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SPRB Spruce Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AEZS Aeterna Zentaris	N/A	5.94	5.93
MNK Mallinckrodt	1.18	0.57	0.31
NRBO NeuroBo Pharmaceuticals	N/A	2.41	2.41
SPRB Spruce Biosciences	0.01	5.36	5.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AEZS Aeterna Zentaris	0.73%
MNK Mallinckrodt	83.74%
NRBO NeuroBo Pharmaceuticals	1.37%
SPRB Spruce Biosciences	91.71%

Insider Ownership

Company	Insider Ownership
AEZS Aeterna Zentaris	0.10%
MNK Mallinckrodt	0.30%
NRBO NeuroBo Pharmaceuticals	1.05%
SPRB Spruce Biosciences	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AEZS Aeterna Zentaris	20	1.79 million	1.79 million	No Data
MNK Mallinckrodt	2,700	13.17 million	13.13 million	Not Optionable
NRBO NeuroBo Pharmaceuticals	10	8.62 million	8.53 million	Not Optionable
SPRB Spruce Biosciences	20	562,000	37.54 million	Optionable

MNK, NRBO, AEZS, and SPRB Headlines

Recent News About These Companies

Head to Head Contrast: Spruce Biosciences (NASDAQ:SPRB) & MusclePharm (OTCMKTS:MSLP)

August 24 at 2:13 AM | americanbankingnews.com

Spruce Biosciences, Inc. (NASDAQ:SPRB) Sees Large Growth in Short Interest

August 18, 2025 | americanbankingnews.com

Comparing Spruce Biosciences (NASDAQ:SPRB) & Zomedica (OTC:ZOMDF)

August 18, 2025 | americanbankingnews.com

Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

August 14, 2025 | businesswire.com

Spruce Biosciences to enact 1-for-75 reverse stock split

July 24, 2025 | msn.com

Spruce Biosciences Announces Reverse Stock Split

July 24, 2025 | finance.yahoo.com

HMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive Disorder

July 22, 2025 | globenewswire.com

SPRB Spruce Biosciences, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

Spruce Biosciences gets conditional approval to resume trading on Nasdaq Capital Market

June 13, 2025 | msn.com

Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market

June 12, 2025 | finance.yahoo.com

Spruce Biosciences’ Compliance Plan Accepted by Nasdaq

June 12, 2025 | tipranks.com

Spruce Biosciences’ SWOT analysis: stock pivots amid clinical setbacks

May 7, 2025 | investing.com

Spruce Biosciences Inc Ordinary Shares

May 6, 2025 | morningstar.comM

Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 6, 2025 | finance.yahoo.com

Spruce Axes 55% of Staff, Leaving Shoestring Crew To Focus on New Rare Disease Asset

April 28, 2025 | biospace.comB

Spruce halves head count, narrowing focus to get ex-BioMarin drug to FDA

April 28, 2025 | fiercebiotech.comF

Spruce Biosciences (SPRB) Receives a Hold from RBC Capital

April 17, 2025 | markets.businessinsider.com

Spruce Biosciences, Inc. (NASDAQ:SPRB) Q1 2023 Earnings Call Transcript

April 17, 2025 | insidermonkey.com

Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

April 15, 2025 | standard-journal.comS

With BioMarin deal, Spruce Biosciences hits reset on rare-disease drug

April 15, 2025 | bizjournals.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNK, NRBO, AEZS, and SPRB Company Descriptions

Aeterna Zentaris NASDAQ:AEZS

$3.29 +0.59 (+21.79%)

As of 08/22/2025

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

Mallinckrodt NYSE:MNK

Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.

NeuroBo Pharmaceuticals NASDAQ:NRBO

$0.65 +0.01 (+1.72%)

As of 08/22/2025

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Spruce Biosciences NASDAQ:SPRB

$8.20 -0.30 (-3.53%)

As of 08/22/2025

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time